EA200300265A1 - Производные хиназолина в качестве ингибиторов киназы - Google Patents

Производные хиназолина в качестве ингибиторов киназы

Info

Publication number
EA200300265A1
EA200300265A1 EA200300265A EA200300265A EA200300265A1 EA 200300265 A1 EA200300265 A1 EA 200300265A1 EA 200300265 A EA200300265 A EA 200300265A EA 200300265 A EA200300265 A EA 200300265A EA 200300265 A1 EA200300265 A1 EA 200300265A1
Authority
EA
Eurasian Patent Office
Prior art keywords
phosphorylation
kinases
inhibit
nitrogen
pharmaceutically acceptable
Prior art date
Application number
EA200300265A
Other languages
English (en)
Other versions
EA005809B1 (ru
Inventor
Синити Иде
Роберт М. Скарборо
Дзунко Ирие
Содзи Ода
Юдзи Номото
Original Assignee
Милленниум Фармасьютикалз, Инк.
Киова Хакко Когио Ко., Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Милленниум Фармасьютикалз, Инк., Киова Хакко Когио Ко., Лтд filed Critical Милленниум Фармасьютикалз, Инк.
Publication of EA200300265A1 publication Critical patent/EA200300265A1/ru
Publication of EA005809B1 publication Critical patent/EA005809B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Настоящее изобретение относится к азотсодержащим гетероциклическим соединениям и их фармацевтически приемлемым солям, которые обладают ингибирующей активностью в отношении фосфорилирования киназ, ингибирующего активность последних. Изобретение относится также к способу ингибирования киназ и лечению болезненных состояний у млекопитающих путем ингибирования фосфорилирования киназ. Особым аспектом настоящего изобретения является обеспечение азотсодержащих гетероциклических соединений и их фармацевтически приемлемых солей, которые ингибируют фосфорилирование рецептора фактора роста из тромбоцитов, для торможения аномального клеточного роста и клеточного блуждания и способ предотвращения или лечения клеточно-пролиферативных заболеваний, таких как артериосклероз, васкулярная реобструкция, рак и гломерулосклероз.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200300265A 2000-08-18 2001-08-17 Производные хиназолина в качестве ингибиторов киназы EA005809B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22612200P 2000-08-18 2000-08-18
PCT/US2001/041752 WO2002016351A1 (en) 2000-08-18 2001-08-17 Quinazoline derivatives as kinase inhibitors

Publications (2)

Publication Number Publication Date
EA200300265A1 true EA200300265A1 (ru) 2003-12-25
EA005809B1 EA005809B1 (ru) 2005-06-30

Family

ID=22847639

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300265A EA005809B1 (ru) 2000-08-18 2001-08-17 Производные хиназолина в качестве ингибиторов киназы

Country Status (25)

Country Link
US (5) US6982266B2 (ru)
EP (3) EP2277877A1 (ru)
JP (1) JP5073147B2 (ru)
KR (1) KR100831116B1 (ru)
CN (1) CN100358890C (ru)
AT (1) ATE402169T1 (ru)
AU (1) AU8544901A (ru)
BR (1) BR0113356A (ru)
CA (1) CA2426440C (ru)
CY (1) CY1110460T1 (ru)
CZ (1) CZ304061B6 (ru)
DE (1) DE60134990D1 (ru)
DK (1) DK1315715T3 (ru)
EA (1) EA005809B1 (ru)
ES (1) ES2311023T3 (ru)
HK (1) HK1057206A1 (ru)
HU (1) HU228668B1 (ru)
IL (2) IL154514A0 (ru)
MX (1) MXPA03001359A (ru)
NO (1) NO323782B1 (ru)
NZ (1) NZ524461A (ru)
PT (1) PT1315715E (ru)
SI (1) SI1315715T1 (ru)
WO (1) WO2002016351A1 (ru)
ZA (1) ZA200301510B (ru)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0113356A (pt) * 2000-08-18 2004-04-20 Millennium Pharm Inc Derivados de quinazolina como inibidores de quinase
DE60143204D1 (de) 2000-08-18 2010-11-18 Kyowa Hakko Kirin Co Ltd N-aryl-ä4-Ä7-(alkoxy)Chinazolin-4-ylÜPiperazinylüCarboxamid-Verbindungen als PDGF-Rezeptoren Hemmer
AU2001293208A1 (en) 2000-08-18 2002-03-04 Cor Therapeutics, Inc. Nitrogenous heterocyclic compounds
JP4564713B2 (ja) * 2000-11-01 2010-10-20 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 窒素性複素環式化合物、ならびに窒素性複素環式化合物およびその中間体を作製するための方法
EP1490362A2 (en) 2001-03-08 2004-12-29 Millennium Pharmaceuticals, Inc. (homo)piperazine substituted quinolines for inhibiting the phosphorylation of kinases
CA2470480C (en) 2001-12-27 2010-12-14 Theravance, Inc. Indolinone derivatives useful as protein kinase inhibitors
AU2003256922A1 (en) * 2002-07-31 2004-02-16 Smithkline Beecham Corporation Substituted heterocyclic compounds as modulators of the ccr5 receptor
JP4588447B2 (ja) 2002-08-09 2010-12-01 セラヴァンス， インコーポレーテッド 過剰増殖および関連疾患に関連するオンコキナーゼ融合ポリペプチド、これをコードする核酸、ならびにこれを検出する方法および同定する方法
CA2571421A1 (en) 2004-06-24 2006-01-05 Nicholas Valiante Compounds for immunopotentiation
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
CA2604284A1 (en) * 2005-04-28 2006-11-02 Supergen, Inc. Protein kinase inhibitors
WO2007012042A1 (en) * 2005-07-20 2007-01-25 Millennium Pharmaceuticals, Inc. New crystal forms of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide
JP2009528365A (ja) * 2006-02-28 2009-08-06 アムゲン インコーポレイティッド ホスホジエステラーゼ１０阻害剤としてのシンノリン及びキナゾリン誘導体
UA95641C2 (en) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
WO2008053270A2 (en) * 2006-10-31 2008-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of an egfr antagonist for the treatment of glomerolonephritis
JP5250901B2 (ja) * 2007-02-23 2013-07-31 学校法人慶應義塾 アニリノキナゾリン系化合物及びその用途
US7998966B2 (en) 2007-04-13 2011-08-16 Supergen, Inc. Axl kinase inhibitors
WO2010059239A2 (en) 2008-11-21 2010-05-27 Millennium Pharmaceuticals, Inc Lactate salt of 4-(6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders
US9416132B2 (en) 2011-07-21 2016-08-16 Tolero Pharmaceuticals, Inc. Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
CN102942529B (zh) * 2012-11-09 2015-06-24 贵州大学 4-(4-取代哌嗪)-5,6,7-三烷氧基喹唑啉类化合物及其制备方法和应用
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
CN103288760B (zh) * 2013-05-16 2015-02-18 苏州明锐医药科技有限公司 卡奈替尼的制备方法
WO2015009889A1 (en) 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
EP3197870B1 (en) 2014-09-25 2020-08-19 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
EA201792214A1 (ru) 2015-04-10 2018-01-31 Араксис Фарма Ллк Соединения замещенного хиназолина
ES2856880T3 (es) 2015-04-15 2021-09-28 Araxes Pharma Llc Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
EP3356354A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10882847B2 (en) 2015-09-28 2021-01-05 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356351A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356347A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356349A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058902A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017070256A2 (en) 2015-10-19 2017-04-27 Araxes Pharma Llc Method for screening inhibitors of ras
AU2016355433C1 (en) 2015-11-16 2021-12-16 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
WO2017100546A1 (en) 2015-12-09 2017-06-15 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
CN106083715A (zh) * 2016-06-01 2016-11-09 谢阳 一种喹啉、喹唑啉类化合物及其药物组合物和应用
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
EP3519402A1 (en) 2016-09-29 2019-08-07 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
JP2019534260A (ja) 2016-10-07 2019-11-28 アラクセス ファーマ エルエルシー Ｒａｓの阻害剤としての複素環式化合物およびその使用方法
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
EP3573964A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
CN110382482A (zh) 2017-01-26 2019-10-25 亚瑞克西斯制药公司 稠合的杂-杂二环化合物及其使用方法
BR112019024674A2 (pt) 2017-05-25 2020-06-16 Araxes Pharma Llc Inibidores covalentes da kras
TW201906832A (zh) 2017-05-25 2019-02-16 美商亞瑞克西斯製藥公司 用於癌症治療之化合物及其使用方法
US11639346B2 (en) 2017-05-25 2023-05-02 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
SG11202009443RA (en) 2018-04-05 2020-10-29 Sumitomo Dainippon Pharma Oncology Inc Axl kinase inhibitors and use of the same
CN108570039B (zh) * 2018-04-25 2022-09-23 上海美迪西生物医药股份有限公司 一类具有抑制抗凋亡蛋白活性的化合物及其制备和应用
CA3127502A1 (en) 2019-02-12 2020-08-20 Sumitomo Dainippon Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
CN115108999B (zh) * 2019-07-26 2023-11-03 暨南大学 一种苯基哌嗪喹唑啉类化合物或其药学上可接受的盐、制法与用途
CN111773440A (zh) * 2020-05-22 2020-10-16 南京大学 一种基于类酶催化反应的抗凝血材料
WO2023081923A1 (en) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0584222B1 (en) 1991-05-10 1997-10-08 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
TW225528B (ru) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
JP4073961B2 (ja) * 1996-10-01 2008-04-09 協和醗酵工業株式会社 含窒素複素環化合物
EP1067123B1 (en) * 1998-03-31 2011-01-19 Kyowa Hakko Kirin Co., Ltd. Nitrogenous heterocyclic compounds
DE60143204D1 (de) 2000-08-18 2010-11-18 Kyowa Hakko Kirin Co Ltd N-aryl-ä4-Ä7-(alkoxy)Chinazolin-4-ylÜPiperazinylüCarboxamid-Verbindungen als PDGF-Rezeptoren Hemmer
BR0113356A (pt) * 2000-08-18 2004-04-20 Millennium Pharm Inc Derivados de quinazolina como inibidores de quinase
WO2002016360A2 (en) 2000-08-18 2002-02-28 Cor Therapeutics, Inc. Nitrogenous heterocyclic compounds
AU2001293208A1 (en) 2000-08-18 2002-03-04 Cor Therapeutics, Inc. Nitrogenous heterocyclic compounds
EP1490362A2 (en) 2001-03-08 2004-12-29 Millennium Pharmaceuticals, Inc. (homo)piperazine substituted quinolines for inhibiting the phosphorylation of kinases
WO2003000188A2 (en) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
US7456189B2 (en) * 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation

Also Published As

Publication number Publication date
US20050288297A1 (en) 2005-12-29
US20130274252A1 (en) 2013-10-17
CZ2003765A3 (cs) 2004-08-18
CZ304061B6 (cs) 2013-09-11
EP1315715A1 (en) 2003-06-04
NO20030747D0 (no) 2003-02-17
EP2277877A1 (en) 2011-01-26
HUP0302615A3 (en) 2008-03-28
AU8544901A (en) 2002-03-04
WO2002016351A1 (en) 2002-02-28
AU2001285449B2 (en) 2007-04-05
JP2005501796A (ja) 2005-01-20
US7560461B2 (en) 2009-07-14
IL154514A (en) 2011-03-31
EP1964839A3 (en) 2008-11-05
CA2426440A1 (en) 2002-02-28
JP5073147B2 (ja) 2012-11-14
EP1315715B1 (en) 2008-07-23
US8324205B2 (en) 2012-12-04
EA005809B1 (ru) 2005-06-30
CY1110460T1 (el) 2015-04-29
NO323782B1 (no) 2007-07-02
HK1057206A1 (en) 2004-03-19
KR100831116B1 (ko) 2008-05-20
EP1964839A2 (en) 2008-09-03
PT1315715E (pt) 2008-10-30
US20100113468A1 (en) 2010-05-06
DK1315715T3 (da) 2008-11-17
CN100358890C (zh) 2008-01-02
DE60134990D1 (de) 2008-09-04
ATE402169T1 (de) 2008-08-15
ES2311023T3 (es) 2009-02-01
US20050101609A1 (en) 2005-05-12
NZ524461A (en) 2004-12-24
IL154514A0 (en) 2003-09-17
HUP0302615A2 (hu) 2003-12-29
CA2426440C (en) 2011-03-15
NO20030747L (no) 2003-04-14
ZA200301510B (en) 2004-06-22
CN1633431A (zh) 2005-06-29
US20150133439A1 (en) 2015-05-14
KR20030082537A (ko) 2003-10-22
US6982266B2 (en) 2006-01-03
SI1315715T1 (sl) 2008-12-31
HU228668B1 (hu) 2013-05-28
MXPA03001359A (es) 2004-12-13
BR0113356A (pt) 2004-04-20

Similar Documents

Publication Publication Date Title
EA200300265A1 (ru) Производные хиназолина в качестве ингибиторов киназы
WO2002072578A3 (en) (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases
EA199900591A1 (ru) АЗОТСОДЕРЖАЩИЕ ГЕТЕРОАРОМАТИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Ха
MY134848A (en) Pyrrolo[2,1-f] [1,2,4] triazine inhibitors of kinases
MX2023007192A (es) Inhibidores de prmt5.
WO2006119507A3 (en) Non-nucleotide composition and method for inhibiting platelet aggregation
TW200613306A (en) Imidazotriazines as protein kinase inhibitors
RU2008119994A (ru) Ингибиторы калиевых каналов
EA200100994A1 (ru) 1-АМИНОТРИАЗОЛО[4,3-а]ХИНАЗОЛИН-5-ОНЫ И/ИЛИ -5-ТИОНЫ, ИНГИБИРУЮЩИЕ ФОСФОДИЭСТЕРАЗУ-IV
DE602005017162D1 (de) 3-arylthioindol-2-carbonsäureamidderivate und ihre analoge als hemmer von caseinkinase i
FR2725719B1 (fr) Diazepino-indoles inhibiteurs de phosphodiesterases iv
DE60143204D1 (de) N-aryl-ä4-Ä7-(alkoxy)Chinazolin-4-ylÜPiperazinylüCarboxamid-Verbindungen als PDGF-Rezeptoren Hemmer
KR890004700A (ko) 포스포디에스테라제 억제제 및 트롬복산 a_2 길항제로 구성된 상승 작용성 배합물 이의 용도 및 이의 제조방법
WO2002016360A3 (en) Nitrogenous heterocyclic compounds
HUP0003679A2 (hu) PKC inhibitorok alkalmazása kardiovaszkuláris megbetegedések kezelésére szolgáló gyógyászati készítmények előállítására
ATE498614T1 (de) (chinazolin-4-yl)piperazin-4-ylüthiocarboxamide als hemmer der phosphorylierung eines pdgf- rezeptors
ATE360423T1 (de) Verwendung von chymase hemmern gegen vaskuläre lipidablagerung
RU2335492C2 (ru) Новые 5,6-дигидропиридин-2-оновые соединения, полезные в качестве ингибиторов тромбина
TH23744B (th) สารยับยั้ง tnf - แอลฟา

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU